$CAUD
Collective Audience, Inc. Stock $caud

$caud Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071597 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$740.8K	$169.8K	$210.9K
YoY Change		-19.51%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$740.8K	$727.7K	$295.8K
YoY Change	-8.27%	145.99%
Operating Profit		-$727.7K	-$295.8K
YoY Change		146.0%
Interest Expense	$467.2K	$329.4K	$430.00
YoY Change	53600.0%	76511.63%
% of Operating Profit
Other Income/Expense, Net			$974.0K
YoY Change
Pretax Income	-$273.6K	-$398.3K	-$245.3K
YoY Change	-67.85%	62.36%
Income Tax	$119.0K
% Of Pretax Income
Net Earnings	-$392.6K	-$398.3K	-$245.3K
YoY Change	-53.86%	62.36%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.13	-$53.37K	-$32.87K
COMMON SHARES
Basic Shares Outstanding	7.462M shares	7.462M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$381.3K	$175.1K	$350.8K
YoY Change	146.09%	-50.1%
Cash & Equivalents	$381.3K	$175.1K	$350.8K
Short-Term Investments
Other Short-Term Assets	$252.5K	$308.5K	$388.2K
YoY Change	-21.5%	-20.52%
Inventory
Prepaid Expenses	$252.5K
Receivables	$1.437M
Other Receivables
Total Short-Term Assets	$633.8K	$483.6K	$739.0K
YoY Change	32.99%	-34.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.43K
YoY Change
Goodwill	$5.991M
YoY Change
Intangibles	$6.755M
YoY Change
Long-Term Investments	$12.84M	$58.18M	$57.34M
YoY Change	-77.6%	1.46%
Other Assets
YoY Change
Total Long-Term Assets	$12.84M	$58.18M	$57.34M
YoY Change	-77.6%	1.46%
TOTAL ASSETS
Total Short-Term Assets	$633.8K	$483.6K	$739.0K
Total Long-Term Assets	$12.84M	$58.18M	$57.34M
Total Assets	$13.48M	$58.66M	$58.08M
YoY Change	-76.69%	1.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$441.7K	$215.6K	$142.5K
YoY Change	-35.75%	51.27%
Accrued Expenses	$2.113M	$1.890M
YoY Change	303.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.555M	$2.106M	$269.2K
YoY Change	271.59%	682.34%
LONG-TERM LIABILITIES
Long-Term Debt	$2.397M	$573.4K	$0.00
YoY Change
Other Long-Term Liabilities	$1.518M	$2.629M	$1.500M
YoY Change	1.18%	75.3%
Total Long-Term Liabilities	$3.914M	$3.203M	$1.500M
YoY Change	160.96%	113.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.555M	$2.106M	$269.2K
Total Long-Term Liabilities	$3.914M	$3.203M	$1.500M
Total Liabilities	$6.469M	$5.309M	$1.769M
YoY Change	174.31%	200.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.836M	-$3.614M
YoY Change	417.53%
Common Stock	$173.00	$173.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.836M	-$2.671M	$56.31M
YoY Change
Total Liabilities & Shareholders Equity	$13.48M	$58.66M	$58.08M
YoY Change	-76.69%	1.0%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$392.6K	-$398.3K	-$245.3K
YoY Change	-53.86%	62.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$362.9K	-$281.7K	-$389.6K
YoY Change	-284.85%	-27.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$45.07M	-$573.4K	-$57.34M
YoY Change	10481806.98%	-99.0%
Cash From Investing Activities	$45.07M	-$573.4K	-$57.34M
YoY Change	10481806.98%	-99.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-45.23M	873.4K	57.96M
YoY Change		-98.49%
NET CHANGE
Cash From Operating Activities	362.9K	-281.7K	-389.6K
Cash From Investing Activities	45.07M	-573.4K	-57.34M
Cash From Financing Activities	-45.23M	873.4K	57.96M
Net Change In Cash	206.2K	18.32K	233.8K
YoY Change	-205.27%	-92.16%
FREE CASH FLOW
Cash From Operating Activities	$362.9K	-$281.7K	-$389.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	aspa	Issuance Of Founder Shares For Related Party Payables IssuanceOfFounderSharesForRelatedPartyPayables		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40723
	dei	Entity Registrant Name EntityRegistrantName	ABRI SPAC I, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2861807
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9663 Santa Monica Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 1091
	dei	Entity Address City Or Town EntityAddressCityOrTown	Beverly Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90210
	dei	City Area Code CityAreaCode	(424)
	dei	Local Phone Number LocalPhoneNumber	732-1021
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	ASPA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7461998	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175074	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154942	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	308543	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321590	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	483617	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	476532	usd
CY2022Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	58175785	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	57340207	usd
CY2022Q3	us-gaap	Assets Assets	58659402	usd
CY2021Q4	us-gaap	Assets Assets	57816739	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	215550	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	163357	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1890273	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	524174	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2105823	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	687531	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	573392	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1100000	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	29459	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	170867	usd
CY2022Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1500000	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1500000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	5308674	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2358398	usd
CY2022Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5733920	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5733920	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56021637	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	52323289	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1728078	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1728078	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1728078	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1728078	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	173	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	173	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	943138	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4262491	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3614220	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1127612	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2670909	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3135052	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58659402	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57816739	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	557941	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	84904	usd
	us-gaap	Professional Fees ProfessionalFees	1959295	usd
	us-gaap	Professional Fees ProfessionalFees	115399	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	169761	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	210911	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	668721	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	211850	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	727702	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	295815	usd
	us-gaap	Operating Expenses OperatingExpenses	2628016	usd
	us-gaap	Operating Expenses OperatingExpenses	327249	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-727702	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-295815	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2628016	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-327249	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	297022	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	432	usd
	us-gaap	Interest Income Other InterestIncomeOther	378995	usd
	us-gaap	Interest Income Other InterestIncomeOther	432	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-32406	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-50082	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-141408	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-50082	usd
CY2022Q3	us-gaap	Interest Income Operating InterestIncomeOperating	329428	usd
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	50514	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	520403	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	50514	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-398274	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-245301	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2107613	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-276735	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-398274	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-245301	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2107613	usd
	us-gaap	Net Income Loss NetIncomeLoss	-276735	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3135052	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1099501	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1322607	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	712944	usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1195374	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-386732	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-869162	usd
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1403473	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-398274	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2670909	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-495	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-495	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-30939	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-6434	usd
CY2021Q3	aspa	Sale Of Units Net Of Underwriting Discounts And Offering Costs SaleOfUnitsNetOfUnderwritingDiscountsAndOfferingCosts	5733920	shares
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	294598	shares
CY2021Q3	aspa	Stock Issued During Period Value Sale Of Private Unitsin Shares StockIssuedDuringPeriodValueSaleOfPrivateUnitsinShares	2945980	usd
CY2021Q3	aspa	Private Warrant Liabilityin Shares PrivateWarrantLiabilityinShares	-176759	usd
CY2021Q3	aspa	Public Warrant Allocation PublicWarrantAllocation	3201884	usd
CY2021Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-602401	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-245301	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	5116968	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2107613	usd
	aspa	Percentage Of Outstanding Voting Rights PercentageOfOutstandingVotingRights	0.50	pure
	us-gaap	Net Income Loss NetIncomeLoss	-276735	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-141408	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-50082	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	378995	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-129856	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	388203	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1418292	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142488	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1079868	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-572532	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	573392	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	57339341	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-573392	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57339341	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1100000	usd
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	573392	usd
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	300000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-300000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	55905720	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2945980	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	100	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	614088	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1673392	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58262712	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	20132	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	350839	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154942	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175074	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	350839	usd
	aspa	Issuance Of Founder Shares For Related Party Payables IssuanceOfFounderSharesForRelatedPartyPayables	25000	usd
	aspa	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-3698348	usd
	aspa	Accretion Of Common Stock To Redemption Value AccretionOfCommonStockToRedemptionValue	-36000	usd
	aspa	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty	50589849	usd
	us-gaap	Stock Issued1 StockIssued1	573392	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abri SPAC I, Inc (“Abri” or the “Company”) was incorporated in the State of Delaware on March 18, 2021. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (our “Initial Business Combination”). The Company has selected December 31 as its fiscal year end. Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Abri SPAC I, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2022, and the date of this filing, the Company had not commenced core operations. All activity for the period from March 18, 2021 (Inception) through September 30, 2022 relates to the Company’s formation and raising funds through its initial public offering (“Initial Public Offering”), which is described below. The Company will not generate any operating revenues until after the completion of the Initial Business Combination, at the earliest. The Company is generating non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration statement pursuant to which the Company registered its securities offered in the Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the Company consummated its Initial Public Offering of 5,000,000 units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $50,000,000 and incurring offering costs of $973,988. The Company granted the underwriter a 45-day option to purchase up to an additional 750,000 Units at the Initial Public Offering price to cover over-allotments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Simultaneously with the consummation of the closing of the Initial Public Offering, the Company completed the private sale of 276,250 units (the “Private Units”) to Abri Ventures I, LLC, the Company’s sponsor (the “Sponsor”) at a purchase price of $10.00 per Private Unit, generating gross proceeds to the Company of $2,762,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the Initial Public Offering on August 12, 2021, an amount of $50,000,000 net proceeds from the Initial Public Offering and sale of the Private Units was placed in a trust account in the United States maintained by Continental Stock Transfer & Trust Company, as trustee (the “Trust Account”). The funds held in the Trust Account were invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations so that we are not deemed to be an investment company under the Investment Company Act. Except with respect to interest earned on the funds held in the Trust Account, the Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the Initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the Initial Business Combination within 12 months from the closing of the Initial Public Offering (or up to 18 months from the closing of this offering with the mandatory extensions of the period of time to consummate an Initial Business Combination) or (B) with respect to any other provision relating to stockholders’ rights or pre-Initial Business Combination activity; or (iii) absent an Initial Business Combination within 12 months from the closing of the Initial Public Offering (or up to 18 months from the closing of this offering with the mandatory extensions of the period of time to consummate an Initial Business Combination), the return of the funds held in the Trust Account to the public stockholders as part of redemption of the public shares. On August 12, 2022, in connection with the first extension, Abri deposited $573,392 (or $0.10 for each share of common stock issued in the IPO) into the trust account of ABRI (the “<b><span style="text-decoration:underline">Trust Account</span></b>”), which holds the net proceeds of the IPO, together with interest earned thereon, less amounts released to pay tax obligations, to extend the time to complete a business combination to November 12, 2022. On November 1, 2022, in connection with the second extension, Abri deposited $573,392 (or $0.10 for each share of common stock issued in the IPO) into the Trust Account to extend the time to complete a business combination to February 12, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2021, the underwriters notified the Company of their intent to exercise of the over-allotment option in part and, on August 23, 2021, the underwriters purchased 733,920 additional Units (the “Additional Units”) at $10.00 per Additional Unit upon the closing of the over-allotment option, generating additional gross proceeds of $7,339,200. On August 23, 2021, simultaneously with the sale of the Additional Units, the Company consummated the sale of an additional 18,348 Private Units at $10.00 per additional Private Unit (the “Additional Private Units”), generating additional gross proceeds of $183,480. A total of $7,339,200 of the net proceeds from the sale of the Additional Units and the Additional Private Units was deposited in the Trust Account, bringing the aggregate proceeds held in the Trust Account on that date to $57,339,200.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock exchange listing rules provide that the Initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the value of the assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable) at the time of the Company signing a definitive agreement in connection with the Initial Business Combination. The Company will only complete an Initial Business Combination if the post-Initial Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect an Initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The payment to the Company’s Sponsor of a monthly fee of $10,000 is for general and administrative services including office space, utilities and secretarial support, which the Company records as operating expense on its statements of operations. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses in connection with our Initial Business Combination. Any such unpaid amount will accrue without interest and be due and payable no later than the date of the consummation of our Initial Business Combination. This arrangement is being agreed to by its Sponsor for our benefit. We believe that the fee charged by our Sponsor is at least as favorable as we could have obtained from an unaffiliated person. This arrangement will terminate upon completion of our Initial Business Combination or the distribution of the Trust Account to our public stockholders. Other than the $10,000 per month fee, no compensation of any kind (including finder’s fees, consulting fees or other similar compensation) will be paid to our insiders, members of our management team or any of our or their respective affiliates, for services rendered to us prior to or in connection with the consummation of our Initial Business Combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations, as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. Since the role of present management after our Initial Business Combination is uncertain, we have no ability to determine what remuneration, if any, will be paid to those persons after our Initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The funds outside of the Trust Account are for our working capital requirements in searching for our Initial Business Combination. The allocation such funds represents our best estimate of the intended uses of these funds. If our estimate of the costs of undertaking due diligence and negotiating our Initial Business Combination is less than the actual amount necessary to do so, we may be required to raise additional capital, the amount, availability and cost of which is currently unascertainable. In this event, we could seek such additional capital through loans or additional investments from our insiders, members of our management team or third parties, but our insiders, members of our management team or third parties are not under any obligation to advance funds to, or invest in, us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will likely use substantially all of the net proceeds of this offering, including the funds held in the Trust Account, in connection with our Initial Business Combination and to pay our expenses relating thereto, including the deferred underwriting commission payable to the underwriter in an amount equal to 3.0% of the total gross proceeds raised in the offering upon consummation of our Initial Business Combination. To the extent that our capital stock is used in whole or in part as consideration to effect our Initial Business Combination, the proceeds held in the Trust Account which are not used to consummate an Initial Business Combination will be disbursed to the combined company and will, along with any other net proceeds not expended, be used as working capital to finance the operations of the target business. Such working capital funds could be used in a variety of ways, including continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent we are unable to consummate an Initial Business Combination, we will pay the costs of liquidation from our remaining assets outside of the Trust Account. If such funds are insufficient, our insiders have agreed to pay the funds necessary to complete such liquidation (currently anticipated to be no more than $15,000) and have agreed not to seek repayment of such expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will not have sufficient available funds to operate for up to the next 12 months (or up to 18 months from the Initial Public Offering if we are required to extend the period of time to consummate an Initial Business Combination), assuming that our Initial Business Combination is not consummated during that time. However, if necessary, in order to meet our working capital needs following the consummation of this offering, our insiders may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of our Initial Business Combination, without interest, or, at the lender’s discretion, up to $750,000 of the notes may be converted upon consummation of our Initial Business Combination into additional Private Warrants at a price of $1.00 per warrant. Notwithstanding, there is no guarantee that the Company will receive such funds. Our stockholders have approved the issuance of the Private Warrants upon conversion of such notes, to the extent the holder wishes to so convert such notes at the time of the consummation of our Initial Business Combination. If we do not complete an Initial Business Combination, any loans and advances from our insiders or their affiliates, will be repaid only from amounts remaining outside our Trust Account, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s Sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their insider shares and any public shares they may hold in connection with the completion of our Initial Business Combination. In addition, our Sponsor and its officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their insider shares if we fail to complete our Initial Business Combination within the prescribed time frame. However, if its Sponsor or any of its officers, directors or affiliates acquire public shares in or after this offering, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if we fail to complete our Initial Business Combination within the prescribed time frame.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon the completion of the Initial Business Combination either (i) in connection with a stockholder meeting called to approve the Initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Initial Business Combination or conduct a tender offer will be made by the Company, solely in the Company’s discretion. The public stockholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the Initial Business Combination including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to the limitations. The amount in the Trust Account is initially anticipated to be approximately $10.00 per public share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock subject to redemption was classified as temporary equity upon the completion of the Initial Public Offering and will subsequently be accreted to redemption value, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with an Initial Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of an Initial Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had 12 months from the closing of the Initial Public Offering (the “Combination Period”) to complete the Initial Business Combination. However, if we were not able to consummate the Initial Business Combination within 12 months, we would extend the period of time to consummate an Initial Business Combination up to two times, each by an additional three months (for a total of up to 18 months to complete an Initial Business Combination). The Sponsor and its affiliates or designees are obligated to fund the Trust Account to extend the time for the Company to complete its Initial Business Combination. On August 5, 2022, the Company deposited $573,392 into the Trust Account to extend the time to complete its Initial Business Combination for an additional three months, or until November 12, 2022. On November 1, 2022, in connection with the second extension, Abri deposited $573,392 (or $0.10 for each share of common stock issued in the IPO) into the Trust Account to extend the time to complete a business combination to February 12, 2023. If the Company is unable to complete its Initial Business Combination within such 18-month period from the closing of the Initial Public Offering or during any mandatory extension period, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the warrants, which will expire worthless if the Company fails to complete its Initial Business Combination within the 12-month time period or during any extension period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks and Uncertainties</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management continues to evaluate the impact of the COVID-19 pandemic and Russia-Ukraine war on the economy and the capital markets and has concluded that, while it is reasonably possible that such events could have negative effects on the Company’s financial position, results of its operations, and/or search for a target company, the specific impacts are not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern and Management Liquidity Plans</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2022, we had cash of $175,074 and a working capital deficit of $1,622,206. Our liquidity needs through the date of this filing had been satisfied through proceeds from notes payable and advances from related party and from the issuance of common stock. Our liquidity needs consist of paying existing accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating an Initial Business Combination. Although certain of our initial stockholders, officers and directors or their affiliates have committed to loan us funds from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, there is no guarantee that we will receive such funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. Further, we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management plans to address this uncertainty during period leading up to the Initial Business Combination. The Company cannot provide any assurance that its plans to raise capital or to consummate an Initial Business Combination will be successful. Based on the foregoing, management believes that the Company will not have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of the Initial Business Combination or one year from this filing. These factors, among others, raise substantial doubt about our ability to continue as a going concern.</p>
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	276250	shares
	aspa	Purchase Price Per Unit PurchasePricePerUnit	10
CY2022Q3	aspa	Deposited Amount DepositedAmount	573392	usd
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.1
CY2021Q3	aspa	Additional Private Sale Units AdditionalPrivateSaleUnits	18348	shares
CY2021Q3	aspa	Additional Private Per Share AdditionalPrivatePerShare	10
CY2021Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	183480	usd
CY2021Q3	aspa	Net Proceeds NetProceeds	7339200	usd
CY2021Q3	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	57339200	usd
	aspa	Percentage Of Fair Market Value PercentageOfFairMarketValue	0.80	pure
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	10000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	10000	usd
	aspa	Total Gross Proceeds Raised Percentage TotalGrossProceedsRaisedPercentage	0.03	pure
	aspa	Repayment Expenses RepaymentExpenses	15000	usd
	aspa	Warrant Price Per Share WarrantPricePerShare	1
	aspa	Public Per Share PublicPerShare	10
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	5000001	usd
CY2022Q3	aspa	Fair Value Of Common Shares Total FairValueOfCommonSharesTotal	110000	shares
	aspa	Fair Value Of Common Shares Total FairValueOfCommonSharesTotal	110000	shares
CY2022Q3	us-gaap	Deposits Deposits	573392	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	175074	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of unaudited financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q3	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-602401	usd
CY2021Q3	aspa	Aggregate Offering Costs AggregateOfferingCosts	973988	usd
CY2021Q3	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	359900	usd
	aspa	Description Of Policy Election DescriptionOfPolicyElection	The Company has made a policy election in accordance with ASC 480-10-S99-3A and will recognize changes in redemption value in additional paid-in capital (or accumulated deficit in the absence of additional paid-in capital) over an 18-month period leading up to an Initial Business Combination. As of September 30, 2022, the Company recorded accretion of $5,431,788 (including a beginning balance on January 1, 2022 of $1,733,440 and $1,403,473 and $3,698,348 during the three and nine months ended September 30, 2022, respectively), with unrecognized accretion remaining of $1,317,563 as of September 30, 2022.
CY2022Q3	aspa	Accretion Accretion	1317563	usd
CY2021Q4	aspa	Accretion Accretion	1733440	usd
CY2021Q4	aspa	Unrecognized Accretion UnrecognizedAccretion	5015911	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	110000	shares
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	943000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	316000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage. As of September 30, 2022 and December 31, 2021, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Derivatives Methods Of Accounting Nonhedging Derivatives DerivativesMethodsOfAccountingNonhedgingDerivatives	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative Financial Instruments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	110000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-2107613	usd
	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-3698348	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	5805961	usd
CY2021Q3	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-245301	usd
CY2022Q3	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-398274	usd
CY2022Q3	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-1403473	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1801747	usd
CY2021Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	847702	usd
	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-276735	usd
	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-602401	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	879136	usd
CY2021Q3	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1250000	usd
CY2021Q3	us-gaap	Other Expenses OtherExpenses	973988	usd
CY2021Q3	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1500000	usd
CY2021Q3	aspa	Additional Shares1 AdditionalShares1	750000	shares
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	276250	shares
	aspa	Purchase Price Per Unit PurchasePricePerUnit	10
	aspa	Proceeds Value Of Initial Public Offering ProceedsValueOfInitialPublicOffering	2762500	usd
CY2021Q3	aspa	Additional Private Sale Units AdditionalPrivateSaleUnits	18348	shares
CY2021Q3	aspa	Additional Value Of Initial Public Offering AdditionalValueOfInitialPublicOffering	183480	usd
CY2021Q3	aspa	Net Proceedss NetProceedss	7339200	usd
CY2022Q2	aspa	Private Units Description PrivateUnitsDescription	the Company’s sponsor, Abri Ventures I, LLC (the “Sponsor”) purchased 1,437,500 shares (the “Founder Shares”) of the Company’s common stock for an aggregate price of $25,000.
CY2021Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	276250	shares
CY2022Q3	us-gaap	Share Price SharePrice	11.5
CY2021Q3	aspa	Additional Sale Amount AdditionalSaleAmount	18348	usd
CY2021Q3	us-gaap	Sale Leaseback Transaction Gross Proceeds Investing Activities SaleLeasebackTransactionGrossProceedsInvestingActivities	183480	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	300000	usd
	aspa	General And Administrative Services GeneralAndAdministrativeServices	10000	usd
CY2022Q3	us-gaap	Payments For Fees PaymentsForFees	30000	usd
	us-gaap	Payments For Fees PaymentsForFees	90000	usd
CY2021Q2	aspa	Founder Shares FounderShares	1437500	shares
CY2021Q2	us-gaap	Partners Capital Distribution Amount Per Share PartnersCapitalDistributionAmountPerShare	0.0001
CY2021Q2	aspa	Total Receivable TotalReceivable	25000	usd
	aspa	Share Subject To Forfeiture ShareSubjectToForfeiture	187500	shares
CY2021Q3	aspa	Additional Private Sale Units AdditionalPrivateSaleUnits	18348	shares
CY2021Q3	aspa	Proceeds From Issuances Initial Public Offering ProceedsFromIssuancesInitialPublicOffering	183480	usd
	aspa	Founder Shares FounderShares	4020	shares
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	114000000	usd
CY2022Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2000000	shares
CY2022Q3	aspa	Common Stock Share Authorized CommonStockShareAuthorized	5000000	shares
CY2022Q3	aspa	Common Stocks Par Or Stated Value Per Share CommonStocksParOrStatedValuePerShare	0.0001
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.021	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2022Q3	us-gaap	Deposits Deposits	573392	usd
CY2022Q4	aspa	Amount Of Deposited AmountOfDeposited	573392	usd
	aspa	Founder Shares Percentage FounderSharesPercentage	0.50	pure
	aspa	Common Stock Equals Or Exceeds Per Shares CommonStockEqualsOrExceedsPerShares	12.5
	aspa	Business Combination Remaining Percentage BusinessCombinationRemainingPercentage	0.50	pure
	aspa	Underwriters Underwriters	100	usd
	aspa	Option To Purchase Share OptionToPurchaseShare	300000	shares
CY2022Q3	aspa	Sale Of Stocks Price Per Shares SaleOfStocksPricePerShares	11.5
	aspa	Expired Term ExpiredTerm	P5Y
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	300000	shares
	aspa	Common Stock Shares CommonStockShares	300000	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	300000	shares
	aspa	Registration Rights RegistrationRights	Notwithstanding the foregoing, the underwriters and their related persons may not (i) have more than one demand registration right at our expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the registration statement.
	us-gaap	Dividends Cash DividendsCash	100	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.118	pure
CY2021Q3	aspa	Proceeds From Issuance Of Share ProceedsFromIssuanceOfShare	100000000	shares
CY2021Q3	us-gaap	Partners Capital Distribution Amount Per Share PartnersCapitalDistributionAmountPerShare	0.0001
CY2021Q3	aspa	Preferred Stock Share Authorized PreferredStockShareAuthorized	1000000	shares
CY2021Q3	aspa	Preferred Stocks Par Or Stated Value Per Share PreferredStocksParOrStatedValuePerShare	0.0001
	aspa	Common Stock Price Per Share CommonStockPricePerShare	11.5
	aspa	Initial Business Combination InitialBusinessCombination	P1Y
	aspa	Warrants Expire WarrantsExpire	P5Y
	aspa	Description Of Warrants For Redemption DescriptionOfWarrantsForRedemption	●at any time while the warrants are exercisable; ●upon a minimum of 30 days’ prior written notice of redemption; ●if, and only if, the last sales price of our shares of common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption; and ●if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.
	aspa	Trigger Price TriggerPrice	16.5
	aspa	Warrant Exercise Price Per Share WarrantExercisePricePerShare	11.5
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	57339200	usd
	aspa	Accretion Of Common Stock Subject To Possible Redemption Amount AccretionOfCommonStockSubjectToPossibleRedemptionAmount	5431782	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56021637	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0425	pure
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3201883	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-3547468	usd
CY2022Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	32406	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	141408	usd
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	170867	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	aspa	Accretion Cost AccretionCost	1403473	usd
	aspa	Accretion Cost AccretionCost	3698348	usd
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	276250	shares
	aspa	Purchase Price Per Unit PurchasePricePerUnit	10
	aspa	Proceeds From Issuance Initial Public Offerings ProceedsFromIssuanceInitialPublicOfferings	2762500	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	aspa	Underwriters Underwriters	100	usd
	aspa	Option To Purchase Share OptionToPurchaseShare	300000	shares
	aspa	Warrants Expire WarrantsExpire	P5Y
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	300000	shares
	aspa	Common Stock Shares CommonStockShares	300000	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	300000	shares
CY2021Q3	aspa	Cash Payment CashPayment	100	usd
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	18348	shares
CY2021Q3	aspa	Proceeds From Issuance Initial Public Offerings ProceedsFromIssuanceInitialPublicOfferings	183480	usd
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	aspa	Fair Value Of Public Warrants Per Share fairValueOfPublicWarrantsPerShare	0.6
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	176759	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	29459	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0119	pure
	aspa	Underlying Common Stock Price UnderlyingCommonStockPrice	9.48
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0082	pure
	aspa	Unit Purchase Price UnitPurchasePrice	10
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y
CY2022Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	58175785	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	29459	usd
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	57340207	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	170867	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.135	pure
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	aspa	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001854583

Files In Submission

Name	View Source	Status
0001213900-22-071597-index-headers.html	Edgar Link	pending
0001213900-22-071597-index.html	Edgar Link	pending
0001213900-22-071597.txt	Edgar Link	pending
0001213900-22-071597-xbrl.zip	Edgar Link	pending
aspa-20220930.xsd	Edgar Link	pending
f10q0922ex31-1_abrispac1.htm	Edgar Link	pending
f10q0922ex31-2_abrispac1.htm	Edgar Link	pending
f10q0922ex32_abrispac1.htm	Edgar Link	pending
f10q0922_abrispac1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
aspa-20220930_def.xml	Edgar Link	unprocessable
aspa-20220930_pre.xml	Edgar Link	unprocessable
aspa-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0922_abrispac1_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aspa-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAUD
Collective Audience, Inc. Stock $caud

2022 Q4 Form 10-Q Financial Statement

#000121390022071597 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAUD Collective Audience, Inc. Stock $caud

2022 Q4 Form 10-Q Financial Statement

#000121390022071597 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAUD
Collective Audience, Inc. Stock $caud